Champions Oncology (CSBR) Q4 FY26 earnings call

Champions Oncology achieved record annual revenue and positive adjusted EBITDA for FY26, driven by strong performance in its core services business and strategic investments in its data platform and therapeutic subsidiary, Corellia. While data revenue saw a year-over-year decline due to a non-recurring prior-year transaction and timing shifts, the company is focused on expanding its customer base and pursuing larger licensing opportunities. The company is actively seeking external funding for Corellia to potentially redeploy investments into other growth initiatives.